Literature DB >> 20570628

Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology.

James P Apland1, Taiza H Figueiredo, Felicia Qashu, Vassiliki Aroniadou-Anderjaska, Adriana P Souza, Maria F M Braga.   

Abstract

Nerve agents are acetylcholinesterase inhibitors, exposure to which causes brain damage, primarily by inducing intense seizure activity. Knowledge of the brain regions that are most vulnerable to nerve agent-induced brain damage can facilitate the development of drugs targeting the protection of these regions. Both the amygdala and the hippocampus have been shown to suffer significant damage after nerve agent exposure, but the amygdala appears to be the more severely affected structure. However, damage in the amygdala has generally been compared with damage in the dorsal hippocampus, whereas there is evidence that the ventral hippocampus is significantly more susceptible to seizures than the dorsal region and, therefore, it may also be more susceptible to nerve agent-induced neuropathology. Here, we report that after status epilepticus induced by soman administration to rats, neuronal degeneration as assessed by Fluoro-Jade C staining was more extensive in the ventral than the dorsal hippocampal subfields, 1 day after soman exposure. Seven days later, the difference between dorsal and ventral regions was not statistically significant. In the amygdala, soman-induced neurodegeneration was more severe in the posteroventral regions of the lateral, basolateral, and medial nuclei compared to the anterodorsal regions of these nuclei. In contrast, the basomedial nucleus was more severely affected in the anterodorsal region. The extent of neurodegeneration in the amygdala was not significantly different from that in the ventral hippocampus. However, when compared with the whole hippocampus, the amygdala displayed more severe neurodegeneration, on both day 1 and day 7 after soman exposure. Testing the protective efficacy of drugs against nerve agent-induced brain damage should include examination of the ventral hippocampus and the posteroventral regions of the amygdala, as these areas are most vulnerable to nerve agent-induced neurodegeneration. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570628      PMCID: PMC2933957          DOI: 10.1016/j.neuro.2010.05.014

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  39 in total

1.  The long-term influence of low-level sarin exposure on behavioral and neurophysiological functions in rats.

Authors:  J Kassa; M Koupilová; J Herink; J Vachek
Journal:  Acta Medica (Hradec Kralove)       Date:  2001

Review 2.  The amygdaloid complex: anatomy and physiology.

Authors:  P Sah; E S L Faber; M Lopez De Armentia; J Power
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

3.  Kainic acid-induced dorsal and ventral hippocampal seizures in rats.

Authors:  K Akaike; S Tanaka; H Tojo; S Fukumoto; S Imamura; M Takigawa
Journal:  Brain Res       Date:  2001-05-04       Impact factor: 3.252

4.  Modification of seizure activity by electrical stimulation. II. Motor seizure.

Authors:  R J Racine
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1972-03

5.  Epileptiform burst responses in ventral vs dorsal hippocampal slices.

Authors:  M Gilbert; R J Racine; G K Smith
Journal:  Brain Res       Date:  1985-12-30       Impact factor: 3.252

6.  Afterdischarge thresholds and kindling rates in dorsal and ventral hippocampus and dentate gyrus.

Authors:  R Racine; P A Rose; W M Burnham
Journal:  Can J Neurol Sci       Date:  1977-11       Impact factor: 2.104

7.  Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs.

Authors:  J H McDonough; L D Zoeffel; J McMonagle; T L Copeland; C D Smith; T M Shih
Journal:  Epilepsy Res       Date:  2000-01       Impact factor: 3.045

8.  Biochemical and behavioral effects of soman vapors in low concentrations.

Authors:  Jiri Bajgar; Lucie Sevelová; Gabriela Krejcová; Josef Fusek; Josef Vachek; Jiri Kassa; Josef Herink; Leo P A de Jong; Hendrik P Benschop
Journal:  Inhal Toxicol       Date:  2004-07       Impact factor: 2.724

9.  Control of nerve agent-induced seizures is critical for neuroprotection and survival.

Authors:  Tsung-Ming Shih; Steven M Duniho; John H McDonough
Journal:  Toxicol Appl Pharmacol       Date:  2003-04-15       Impact factor: 4.219

10.  Diazepam administration after prolonged status epilepticus reduces neurodegeneration in the amygdala but not in the hippocampus during epileptogenesis.

Authors:  Felicia Qashu; Taiza H Figueiredo; Vassiliki Aroniadou-Anderjaska; James P Apland; Maria F M Braga
Journal:  Amino Acids       Date:  2009-01-07       Impact factor: 3.520

View more
  29 in total

1.  Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Cara H Olsen; Maria F M Braga
Journal:  Neurotox Res       Date:  2017-08-03       Impact factor: 3.911

2.  The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Franco Rossetti; Steven L Miller; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2014-08-25       Impact factor: 4.030

3.  Pathophysiological mechanisms underlying increased anxiety after soman exposure: reduced GABAergic inhibition in the basolateral amygdala.

Authors:  Eric M Prager; Volodymyr I Pidoplichko; Vassiliki Aroniadou-Anderjaska; James P Apland; Maria F M Braga
Journal:  Neurotoxicology       Date:  2014-08-20       Impact factor: 4.294

4.  Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents.

Authors:  Xin Wu; Ramkumar Kuruba; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2018-08-16       Impact factor: 4.030

5.  Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.

Authors:  T H Figueiredo; V Aroniadou-Anderjaska; F Qashu; J P Apland; V Pidoplichko; D Stevens; T M Ferrara; M F M Braga
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

6.  A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.

Authors:  Steven L Miller; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Camila P Almeida-Suhett; James P Apland; Maria F M Braga
Journal:  Toxicol Appl Pharmacol       Date:  2015-02-15       Impact factor: 4.219

7.  Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Volodymyr I Pidoplichko; Katia Rossetti; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2018-02-21       Impact factor: 4.030

8.  A rodent model of human organophosphate exposure producing status epilepticus and neuropathology.

Authors:  W Pouliot; S L Bealer; B Roach; F E Dudek
Journal:  Neurotoxicology       Date:  2016-08-12       Impact factor: 4.294

9.  Oral Pretreatment with Galantamine Effectively Mitigates the Acute Toxicity of a Supralethal Dose of Soman in Cynomolgus Monkeys Posttreated with Conventional Antidotes.

Authors:  Malcolm Lane; D'Arice Carter; Joseph D Pescrille; Yasco Aracava; William P Fawcett; G William Basinger; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2020-08-05       Impact factor: 4.030

10.  Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Carol E Green; Robert Swezey; Chun Yang; Felicia Qashu; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2012-10-05       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.